GlassScriptPhysician profile
Jeffrey Rogers Leipzig
NPI 1750325718
$4,435.92
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $589 · 2021: $1,048 · 2022: $1,196 · 2023: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $993.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $659.78 | 2021-2023 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $534.76 | 2019-2022 | |
| Genzyme Corporation | $383.26 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $316.65 | 2019-2020 | |
| Optinose US, INC. | $254.49 | 2019-2022 | |
| Alk-Abello, INC | $251.19 | 2019-2022 | |
| Pfizer INC. | $210.05 | 2019-2022 | |
| Covis Pharma Gmbh | $131.82 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $129.60 | 2023 | Tremfya |
| Amarin Pharma, INC. | $90.86 | 2019 | |
| Celgene Corporation | $82.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.39 | 2019-2022 | |
| Grifols USA, LLC | $49.90 | 2022 | |
| Biocryst US Sales Co., LLC | $46.07 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.09 | 2021-2022 | |
| Csl Behring | $36.98 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.30 | 2022 | |
| Kaleo, INC. | $29.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $14.89 | 2021 | |
| Hikma Pharmaceuticals USA | $13.46 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Leipzig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.